Allosteric Modulators Market Report 2026

Allosteric Modulators Market Overview

• Allosteric Modulators market size has reached to $1.82 billion in 2025 • Expected to grow to $3.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.7% • Growth Driver: Increasing Burden Of Neurological Disorders And Disability Fueling The Growth Of The Market Due To Rising Demand For Advanced Neurological Disorder Treatments • Market Trend: Brain-Penetrant Allosteric Modulators Supporting Precision Neurology Therapies • Asia-Pacific was the largest region and fastest growing region.

What Is Covered Under Allosteric Modulators Market?

Allosteric modulators are compounds that bind to a site on a receptor or protein that is different from the active (orthosteric) binding site and regulate receptor activity by enhancing or reducing the response to endogenous ligands. These modulators influence receptor conformation and signaling pathways without directly activating the primary binding site, offering greater selectivity and potentially fewer side effects compared to conventional drugs. The main types of allosteric modulators include positive allosteric modulators, negative allosteric modulators, and silent allosteric modulators. Positive allosteric modulators refer to compounds that bind to a site distinct from the active site of a target protein and enhance its biological activity. The various applications involved are neurological disorders, oncology, cardiovascular diseases, metabolic disorders, and others and they are utilized by end users including pharmaceutical companies, biotechnology companies, academic and research institutes, and others.

What Is The Allosteric Modulators Market Growth Forecast?

The allosteric modulators market size is expected to see rapid growth in the next few years. It will grow to $3.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expansion of AI-driven drug discovery platforms, increasing investment in precision medicine and targeted therapeutics, rising clinical trials for allosteric modulators, growth in computational biology and structural pharmacology, increasing demand for high selectivity drugs with fewer side effects. Major trends in the forecast period include increasing adoption of structure-based drug design for allosteric modulator discovery, growing use of computational chemistry and AI-driven molecular screening in receptor targeting, expansion of allosteric modulator research in neurological disorder therapeutics, rising development of highly selective receptor subtype-specific modulators, increasing pharmaceutical focus on safer next-generation non-orthosteric drug mechanisms.

Global Allosteric Modulators Market Segmentation

1) By Type: Positive Allosteric Modulators, Negative Allosteric Modulators, Silent Allosteric Modulators 2) By Application: Neurological Disorders, Oncology, Cardiovascular Diseases, Metabolic Disorders, Other Applications 3) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes, Other End Users Subsegments: 1) By Positive Allosteric Modulators: Metabotropic Glutamate Receptor Modulators, Gamma Aminobutyric Acid Receptor Modulators, Nicotinic Acetylcholine Receptor Modulators, Calcium Sensing Receptor Modulators 2) By Negative Allosteric Modulators: Serotonin Receptor Modulators, Dopamine Receptor Modulators, Histamine Receptor Modulators, Chemokine Receptor Modulators 3) By Silent Allosteric Modulators: Metabotropic Glutamate Receptor Modulators, Gamma Aminobutyric Acid Receptor Modulators, Nicotinic Acetylcholine Receptor Modulators

What Are The Drivers Of The Allosteric Modulators Market?

The increasing burden of neurological disorders and disability is expected to propel the growth of the allosteric modulators market going forward. Neurological disorders and disability refer to medical conditions affecting the brain, spinal cord, and nervous system that result in cognitive, sensory, or physical impairments. The burden of neurological disorders and disability is increasing due to rising chronic disease prevalence and growing lifestyle related health risks. Allosteric modulators are used in neurological disorders to regulate receptor activity and improve neurotransmission, helping manage conditions such as epilepsy, schizophrenia, Parkinson’s disease, and anxiety disorders. For instance, in March 2024, according to the Alzheimer’s Association, a US-based nonprofit health organization, an estimated 6.9 million Americans aged 65 years and older were living with Alzheimer’s disease in 2024, compared to 6.7 million in 2023, reflecting a notable year-on-year increase in disease prevalence. Therefore, the increasing burden of neurological disorders and disability is driving the growth of the allosteric modulators industry. The increasing healthcare spending is expected to propel the growth of the allosteric modulators market going forward. Healthcare spending refers to the total expenditure on medical services, treatments, healthcare infrastructure, pharmaceuticals, and related activities aimed at maintaining or improving health. Healthcare spending is rising due to the increasing prevalence of chronic diseases, as long-term conditions such as diabetes, cardiovascular disorders, and cancer require continuous medical care, advanced treatments, and prolonged hospitalization. Higher healthcare spending supports allosteric modulators by expanding funding and reimbursement capacity for advanced precision therapies, enabling greater investment in research, clinical trials, and adoption of novel mechanism-based drugs that target diseases with improved specificity and fewer side effects. For instance, in April 2026, according to the Office for National Statistics, a UK-based government agency, healthcare spending accounted for 11.4% of GDP in 2025, up from 11.1% in 2024. Therefore, the increasing healthcare spending is driving the growth of the allosteric modulators industry.

Key Players In The Global Allosteric Modulators Market

Major companies operating in the allosteric modulators market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Neurocrine Biosciences Inc., Intra-Cellular Therapies, Biohaven Ltd., Nxera Pharma, Kainova Therapeutics, Saniona AB, Addex Therapeutics Ltd., Confo Therapeutics NV

Global Allosteric Modulators Market Trends and Insights

Major companies operating in the allosteric modulators market are focusing on developing innovative solutions, such as selective allosteric modulator therapeutics to meet the rising demand for safer and more targeted neurological disorder treatments. Selective allosteric modulators bind to receptor sites different from traditional active binding sites enabling improved precision enhanced efficacy and reduced side effects compared to conventional drugs. For instance, in April 2024, Neurosterix, a US-based biopharmaceutical company, launched an advanced allosteric modulator drug discovery platform supported by 63 million dollars in Series A financing. The platform focuses on developing highly selective brain-penetrant small molecule therapies including M4 positive allosteric modulators for schizophrenia and other neurological disorders. The technology utilizes high-throughput discovery tools to accelerate the development of next-generation neurological therapeutics with improved tolerability and therapeutic precision.

Regional Outlook

Asia-Pacific was the largest region in the allosteric modulators market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Allosteric Modulators Market?

The allosteric modulators market consists of sales of G protein-coupled receptor (GPCR) modulators, ion channel modulators, enzyme modulators, receptor-targeted therapeutics, and small molecule allosteric drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Allosteric Modulators Market Report 2026?

The allosteric modulators market research report is one of a series of new reports from The Business Research Company that provides allosteric modulators market statistics, including allosteric modulators industry global market size, regional shares, competitors with a allosteric modulators market share, detailed allosteric modulators market segments, market trends and opportunities, and any further data you may need to thrive in the allosteric modulators industry. This allosteric modulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.